Rovi Pharmaceuticals Laboratories

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Sep 21, 2026

Completed

Pharmacokinetics, Safety, and Tolerance Study of Single Dose Administration of Risperidone ISM®

Sep 12, 2026

Recruiting

An Open-Label, One-Sequence Study to Evaluate the Steady-State Comparative Bioavailability of Quarterly Letrozole SIE and Once Daily 2.5 mg Oral Letrozole (Femara®) in Post-Menopausal Women Treated With Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. (SIE-1)

Earlier

Jul 25, 2026TrialA Phase I, Open Label, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Intramuscular Injections of Letrozole LEBE at Different Strengths in Voluntary Healthy Post-Menopausal Women.

May 1, 2026TrialA Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Palbociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Advanced Breast Cancer

Sep 26, 2023TrialPharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia

Oct 18, 2022TrialNon-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse

Mar 9, 2021TrialComparative Bioavailability of Risperidone.

Jul 9, 2018TrialComparative Bioavailability of Risperidone

3 more events

Nov 6, 2017TrialEvaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)

Aug 25, 2017TrialStudy to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

Jun 2, 2017TrialStudy to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

Details